These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17439935)

  • 21. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
    Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
    J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease.
    Durongpisitkul K; Jakrapanichakul D; Sompradikul S
    J Med Assoc Thai; 2008 Feb; 91(2):196-202. PubMed ID: 18389984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
    Channick RN; Olschewski H; Seeger W; Staub T; Voswinckel R; Rubin LJ
    J Am Coll Cardiol; 2006 Oct; 48(7):1433-7. PubMed ID: 17010807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Consecutive use of sildenafil and bosentan for the treatment of pulmonary arterial hypertension associated with collagen vascular disease: sildenafil as reliever and bosentan as controller.
    Kamata Y; Iwamoto M; Minota S
    Lupus; 2007; 16(11):901-3. PubMed ID: 17971364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21.
    Kermeen FD; Franks C; O'Brien K; Seale H; Hall K; McNeil K; Radford D
    Heart Lung Circ; 2010 Oct; 19(10):595-600. PubMed ID: 20728407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
    McLaughlin VV
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.
    Provencher S; Sitbon O; Humbert M; Cabrol S; Jaïs X; Simonneau G
    Eur Heart J; 2006 Mar; 27(5):589-95. PubMed ID: 16431875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease.
    Ahmadi-Simab K; Hellmich B; Gross WL
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():44-8. PubMed ID: 16919010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term outcome and effects of oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension.
    Hsu HH; Chen JS; Chen RJ; Ko WJ; Kuo SW; Wu ET; Wu MH; Wang JK; Lee YC
    Respir Med; 2007 Jul; 101(7):1556-62. PubMed ID: 17223329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses.
    Karavolias GK; Georgiadou P; Gkouziouta A; Kariofillis P; Karabela G; Tsiapras D; Sbarouni E; Chaidaroglou A; Degiannis D; Adamopoulos S; Voudris V
    Expert Opin Ther Targets; 2010 Dec; 14(12):1283-9. PubMed ID: 20958219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and tolerability of bosentan in adults with Eisenmenger physiology.
    Gatzoulis MA; Rogers P; Li W; Harries C; Cramer D; Ward S; Mikhail GW; Gibbs JS
    Int J Cardiol; 2005 Jan; 98(1):147-51. PubMed ID: 15676179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era.
    Jacobs W; Boonstra A; Brand M; Rosenberg DM; Schaaf B; Postmus PE; Vonk Noordegraaf A
    J Heart Lung Transplant; 2010 Oct; 29(10):1150-8. PubMed ID: 20580264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension.
    Hoeper MM; Faulenbach C; Golpon H; Winkler J; Welte T; Niedermeyer J
    Eur Respir J; 2004 Dec; 24(6):1007-10. PubMed ID: 15572546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study.
    Apostolopoulou SC; Manginas A; Cokkinos DV; Rammos S
    Heart; 2007 Mar; 93(3):350-4. PubMed ID: 16980516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
    Channick RN; Simonneau G; Sitbon O; Robbins IM; Frost A; Tapson VF; Badesch DB; Roux S; Rainisio M; Bodin F; Rubin LJ
    Lancet; 2001 Oct; 358(9288):1119-23. PubMed ID: 11597664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.
    Galiè N; Rubin Lj; Hoeper M; Jansa P; Al-Hiti H; Meyer G; Chiossi E; Kusic-Pajic A; Simonneau G
    Lancet; 2008 Jun; 371(9630):2093-100. PubMed ID: 18572079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy.
    Seyfarth HJ; Pankau H; Hammerschmidt S; Schauer J; Wirtz H; Winkler J
    Chest; 2005 Aug; 128(2):709-13. PubMed ID: 16100158
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy.
    Schulze-Neick I; Gilbert N; Ewert R; Witt C; Gruenig E; Enke B; Borst MM; Lange PE; Hoeper MM
    Am Heart J; 2005 Oct; 150(4):716. PubMed ID: 16209972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.
    Kemp K; Savale L; O'Callaghan DS; Jaïs X; Montani D; Humbert M; Simonneau G; Sitbon O
    J Heart Lung Transplant; 2012 Feb; 31(2):150-8. PubMed ID: 22138355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term bosentan in chronic thromboembolic pulmonary hypertension.
    Seyfarth HJ; Hammerschmidt S; Pankau H; Winkler J; Wirtz H
    Respiration; 2007; 74(3):287-92. PubMed ID: 16699254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.